S 23521 decreases food intake and body weight gain in diet-induced obese rats

Obesity Research

Volumn 12, Issue 10, 2004, Pages 1596-1603

  Claret, Marc ^a   Corominola, Helena ^a   Canals, Ignasi ^a   Nadal, Belén ^a   Chavanieu, Alain ^b   Pfeiffer, Bruno ^c   Renard, Pierre ^c   Gorostiaga, Carmen ^c   Delagrange, Philippe ^c   Grassy, Gérard ^b   Gomis, Ramon ^a,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CNRS   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Adiposity; Gene expression; Glucose tolerance; Insulin sensitivity

Indexed keywords

ANTIOBESITY AGENT; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (7 36); GLUCAGON-LIKE PEPTIDE 1 (7-36); PEPTIDE FRAGMENT;

ADIPOSE TISSUE; ANIMAL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; EATING; ENERGY METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; OBESITY; PHYSIOLOGY; RANDOMIZATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; WEIGHT GAIN; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; OBESITY; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TIME FACTORS; WEIGHT GAIN;

EID: 16644375263     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2004.199     Document Type: Article

References (32)

1. Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with possible therapeutic perspective. Acta Diabetol 1998;35:117-29.
2. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142:521-7.
3. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol. 2002;440:269-79.
4. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology. 1987;121:1076-82.
5. 2 in the central control of feeding behaviour. Digestion. 1993;54(Suppl 1):360-1.
6. Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V, Classen M. Glucagon-like-peptide (GLP)-1-(7-36)-amide: a central suppressor of food intake in rats. Gastroenterology. 1992;102(Suppl 1):A756.
7. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.
8. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 1998;779:75-83.
9. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3586-96.
10. Rodriguez de Fonseca F, Navarro M, Alvarez E, et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonist on satiety and body weight loss in Zucker obese rats. Metabolism. 2000;49:709-17.
11. Sarrauste De Menthiere C, Chavanieu A, et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH(2) for receptor interaction and cAMP production. Eur J Med Chem. 2004;39:473-80.
12. Al-Barazanji KA, Arch JRS, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res. 2000;8:267-323.
13. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerated food intake, weight gain and fat deposition in Zucker rats. Endocrinology. 2000;141:1936-41.
14. Larson PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50:2530-9.
15. Young AA, Gedulin BR, Bhavsar S, et al. Glucose lowering and insulin-sensitizing actions of exendin-4. Diabetes. 1999;48:1026-34.
16. Claret M, Corominola H, Casamitjana R, Gomis R. Tung-state treatment reduces body weight in diet-induced obesity. Diabetologia. 2001;44(Suppl 1):A182.
17. Meeran K, O'Shea D, Edwards CMB, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology. 1999;140:244-50.
18. Thiele TE, Van Dijk G, Campfield LA, et al. Central infusión of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol. 1997;272:R726-30.
19. Mizuno A, Kuwajima M, Ishida K, et al. Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism. 1997;46:745-9.
20. Olefsky JM, Saltiel AR. PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab. 2000;11:362-8.
21. Claire M, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002;13:18-23.
22. Redonnet A, Groubet R, Noel-Suberville C, Bonilla S, Martinez A, Higueret P. Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear receptors in the rat. Metabolism. 2001;50:1161-7.
23. Ukkola O. Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 2002;147:571-4.
24. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194-8.
25. Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun. 2001;281:1220-5.
26. O'Shea D, Gunn I, Chen X, Bloom S, Herbert JA. A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport. 1996;7:830-2.
27. Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD. Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides. 1998;19:869-75.
28. Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V. Glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to supress feeding in rats. Am J Physiol. 2003;284:R1427-35.
29. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18:7-14.
30. 131I-Glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol. 1999;26:413-20.
31. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27:313-8.
32. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45:832-5.